Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00262613 · ClinicalTrials.gov registry record · Phase 2
Sodium Pyruvate Therapy in COPD Patients
A Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Emphy.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT00262613 is a Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD) that has completed, run by Emphy. The registered enrollment target is 60 participants, below the 650-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00262613, a Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD), has completed, sponsored by Emphy.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
In animal models, sodium pyruvate has been shown to be an effective anti-inflammatory agent, and in human studies sodium pyruvate has been shown to be a bronchodilating agent. Subjects with COPD are known to have inflammation in the lung, and often have bronchoconstriction. As such, these subjects typically are on multiple therapies, including steroid therapy. This trial will study the effect of inhaled sodium pyruvate on inflammation and lung function in COPD subjects over a six week period.
Conditions Studied
Interventions
- DRUG sodium pyruvate in 0.9% sodium chloride solution
Study Locations (2)
Connecticut
- Hospital for Special Care - New Britain
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2004-09 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00262613
The ClinicalTrials.gov registry entry for NCT00262613 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 650-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (91% lower). The listed sponsor is Emphy, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 1 intervention - of which sodium pyruvate in 0.9% sodium chloride solution is the first listed.
NCT00262613 reports 2 study locations spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00262613 about?
NCT00262613 is a clinical study titled "Sodium Pyruvate Therapy in COPD Patients". In animal models, sodium pyruvate has been shown to be an effective anti-inflammatory agent, and in human studies sodium pyruvate has been shown to be a bronchodilating agent. Subjects with COPD are known to have inflammation in the lung, and often have bronchoconstriction. As such, these subjects t...
What is the current status of trial NCT00262613?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2004-09. Estimated completion is 2006-05.
What conditions does trial NCT00262613 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT00262613?
The interventions under investigation include: sodium pyruvate in 0.9% sodium chloride solution (DRUG).
Who is sponsoring clinical trial NCT00262613?
This trial is sponsored by Emphy, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00262613 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
RECRUITING · Phase 2
-
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 2
-
Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)
COMPLETED · Phase 2
-
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
COMPLETED · Phase 2
-
Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 2
-
Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.